Avicanna Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVCN.TO research report →
Companywww.avicanna.com
Avicanna Inc. , a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions.
- CEO
- Aras Azadian Mba
- IPO
- 2019
- Employees
- 87
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $16.35M
- P/E
- -4.31
- P/S
- 0.63
- P/B
- 4.00
- EV/EBITDA
- -6.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 51.34%
- Op Margin
- -12.95%
- Net Margin
- -13.90%
- ROE
- -116.09%
- ROIC
- -25.02%
Growth & Income
- Revenue
- $25.48M · 0.08%
- Net Income
- $-2,844,215 · 21.39%
- EPS
- $-0.02 · 31.49%
- Op Income
- $-2,715,995
- FCF YoY
- 51.28%
Performance & Tape
- 52W High
- $0.31
- 52W Low
- $0.12
- 50D MA
- $0.15
- 200D MA
- $0.22
- Beta
- 0.32
- Avg Volume
- 89.39K
Get TickerSpark's AI analysis on AVCN.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AVCN.TO Coverage
We haven't published any research on AVCN.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AVCN.TO Report →